Innovative Treatment Research Articles

Types of learning and varieties of innovation: how does policy learning enable policy innovation?

Policy innovation is considered important for addressing major challenges such as climate change and the sustainable energy transition. Although policy learning is likely to play a key role in enabling policy innovation, the link between them remains unclear despite much research on both topics. To address this gap, we move beyond a binary treatment of policy innovation and differentiate policy problem innovation from policy instrument innovation and policy process innovation. Subsequently, we synthesise the literature on policy learning with the research on the multiple streams framework (MSF), a well-known lens for explaining policy innovation. Like earlier policy learning studies, we distinguish several types of learning by posing the key questions of learning, but in the context of each stream of the MSF: who learns (actors), what (beliefs), how (modes), and to what effect (ripening). This new conceptualisation clarifies the relationship of each type of policy learning to the varieties of policy innovation. Further, it indicates that policy learning is likely to result in policy innovation if and only if it influences the coupling among the three streams during a window of opportunity – through policy entrepreneurship – and not otherwise. We conclude with the implications of this study for future research on policy innovation, policy learning, and the MSF.

Application of Quercetin and its Novel Formulations in the Treatment of Malignancies of Central Nervous System: An Updated Review of Current Evidence based on Molecular Mechanisms.

Quercetin, a naturally occurring polyphenolic compound found in abundance in vegetables and fruits, has emerged as a compelling subject of study in cancer treatment. This comprehensive review delves into the significance and originality of quercetin's multifaceted mechanisms of action, with a particular focus on its application in various brain tumors such as glioblastoma, glioma, neuroblastoma, astrocytoma, and medulloblastoma. This review scrutinizes the distinctive facets of quercetin's anti-cancer properties, highlighting its capacity to modulate intricate signaling pathways, trigger apoptosis, impede cell migration, and enhance radiosensitivity in brain tumor cells. Significantly, it synthesizes recent research findings, providing insights into potential structure-activity relationships that hold promise for developing novel quercetin derivatives with heightened effectiveness. By unraveling the unique attributes of quercetin's anti-brain tumor effects and exploring its untapped potential in combination therapies, this review contributes to a deeper comprehension of quercetin's role as a prospective candidate for advancing innovative treatments for brain cancer.

Hyperoxic-hypoxic Paradox: Breast Cancer Microenvironment and an Innovative Treatment Strategy.

A small therapeutic range of oxygen is required for effective metabolism. As a result, hypoxia (low oxygen concentration) is one of the most potent inducers of gene expression, metabolic alterations, and regenerative processes, such as angiogenesis, stem cell proliferation, migration, and differentiation. The cellular response is controlled by sensing the increased oxygen levels (hyperoxia) or hypoxia via specific chemoreceptor cells. Surprisingly, changes in free oxygen concentration instead of absolute oxygen levels may be regarded as a deficiency of oxygen at the cellular level. Recurrent intermittent hyperoxia may trigger many mediators of cellular pathways typically generated during hypoxia. The dilemma of hyperoxic-hypoxic conditions is known as the hyperoxic-hypoxic paradox. According to the latest data, the hypoxic microenvironment, crucial during cancer formation, has been demonstrated to play a key role in regulating breast cancer growth and metastasis. Hypoxic circumstances cause breast cancer cells to respond in a variety of ways. Transcription factors are identified as hypoxia-inducible factors (HIFs) that have been suggested to be a factor in the pathobiology of breast cancer and a possible therapeutic target, driving the cellular response to hypoxia. Breast cancer has a dismal prognosis due to a high level of resistance to practically all well-known cancer management that has been related to hypoxia-based interactions between tumor cells and the stromal milieu. We attempt to review the enigma by exploring the starring roles of HIFs in breast cancer, the HIF paradox, and the hyperoxic-hypoxic enigma.

Quantifying the Value of Technology and Policy Innovation in Water Resource Portfolios

AbstractRecent water infrastructure planning models demonstrate that explicitly accounting for hydrological changes in long‐term water planning reduces costs and increases system robustness. However, current models do not consider the effects of other changes occurring in the system over long time horizons, namely technology and policy innovation. By leveraging state‐of‐the‐art dynamic control techniques, we propose a suite of tools that explicitly relate hydrologic change, technology innovation, and policy interventions to system‐level water costs. We design robust and cost‐optimal strategies for water supply expansion under hydrological variability and hundreds of plausible innovation states, for example, treatment cost and diversification improvements, deployment times, and demand reduction campaigns. Our approach circumvents the need to pre‐assign probabilities to innovation scenarios and, instead, directly calculates the effects of technology, policy, and hydrology variations on system cost and planning strategies to identify avenues of impactful innovation. These tools can support technology development hubs, urban, state, and federal water planners in anticipating cost implications of technology and policy innovation at the local level, and prioritizing high‐impact innovation goals based on quantitative targets. Results for the case study of Santa Barbara, California identify high‐value innovation attributes for the city as well as combinations of innovation attributes across technologies and policies, and quantify their potential utility cost reductions.

Epigenetics of Fear, Anxiety and Stress - Focus on Histone Modifications.

Fear-, anxiety- and stress-related disorders are among the most frequent mental disorders. Given substantial rates of insufficient treatment response and often a chronic course, a better understanding of the pathomechanisms of fear-, anxiety- and stress-related disorders is urgently warranted. Epigenetic mechanisms such as histone modifications - positioned at the interface between the biological and the environmental level in the complex pathogenesis of mental disorders - might be highly informative in this context. The current state of knowledge on histone modifications, chromatin-related pharmacology and animal models modified for genes involved in the histone-related epigenetic machinery will be reviewed with respect to fear-, anxiety- and stress-related states. Relevant studies, published until 30th June 2022, were identified using a multi-step systematic literature search of the Pub- Med and Web of Science databases. Animal studies point towards histone modifications (e.g., H3K4me3, H3K9me1/2/3, H3K27me2/3, H3K9ac, H3K14ac and H4K5ac) to be dynamically and mostly brain region-, task- and time-dependently altered on a genome-wide level or gene-specifically (e.g., Bdnf) in models of fear conditioning, retrieval and extinction, acute and (sub-)chronic stress. Singular and underpowered studies on histone modifications in human fear-, anxiety- or stress-related phenotypes are currently restricted to the phenotype of PTSD. Provided consistent validation in human phenotypes, epigenetic biomarkers might ultimately inform indicated preventive interventions as well as personalized treatment approaches, and could inspire future innovative pharmacological treatment options targeting the epigenetic machinery improving treatment response in fear-, anxiety- and stressrelated disorders.

Innovative Treatment of Crack Defects and Skid Resistant Deficiencies in Old Asphalt Pavement Using a Prefabricated Flexible Ultrathin Overlay

Innovative Treatment of Crack Defects and Skid Resistant Deficiencies in Old Asphalt Pavement Using a Prefabricated Flexible Ultrathin Overlay

Multimodal Tetrahedral DNA Nanoplatform for Surprisingly Rapid and Significant Treatment of Acute Liver Failure.

Acute liver failure (ALF) is a life-threatening disease associated with the rapid development of inflammatory storms, level elevation of reactive oxygen species (ROS), and hepatocyte necrosis, which results in high short-term mortality. Except for liver transplantation, no effective strategies are available for ALF therapy due to the rapid disease progression and narrow window of therapeutic time. Therefore, there is an urgent demand to explore the fast and effective modalities for ALF treatment. Herein, a multifunctional tetrahedral DNA nanoplatform (TDN) is constructed by incorporating tumor necrosis factor-α siRNA (siTNF-α) through DNA hybridization and antioxidant manganese porphyrin (MnP4) via π-π stacking interaction with G-quadruplex (G4) for surprisingly rapid and significant ALF therapy. TDN-siTNF-α/-G4-MnP4 silences TNF-α of macrophages by siTNF-α and polarizes them to the anti-inflammatory M2 phenotype, providing appropriate microenvironments for hepatocyte viability. Additionally, TDN-siTNF-α/-G4-MnP4 scavenges intracellular ROS by MnP4, protecting hepatocytes from oxidative-stress-associated cell death. Furthermore, TDN itself promotes hepatocyte proliferation by modulating the cell cycle. TDN-siTNF-α/-G4-MnP4 shows almost complete liver accumulation after intravenous injection and exhibits excellent therapeutic efficacy of ALF within 2h. The multifunctional DNA nanoformulation provides an effective strategy for rapid ALF therapy, expanding its application for innovative treatments of liver diseases.

Exploring the ferroptosis-related gene lipocalin 2 as a potential biomarker for sepsis-induced acute respiratory distress syndrome based on machine learning

BackgroundSepsis is a major cause of mortality in patients, and ARDS is one of the most common outcomes. The pathophysiology of acute respiratory distress syndrome (ARDS) caused by sepsis is significantly impacted by genes related to ferroptosis. MethodsIn this study, Weighted gene co-expression network analysis (WGCNA), protein-protein interaction (PPI) networks, functional enrichment analysis, and machine learning were employed to identify characterized genes and to construct receiver operating characteristic (ROC) curves. Additionally, DNA methylation levels were quantified and single-cell analysis was conducted. To validate the alterations in the expression of Lipocalin-2 (LCN2) and ferroptosis-related proteins in the in vitro model, Western blotting was carried out, and the changes in intracellular ROS and Fe2+ levels were detected. ResultsA combination of eight machine learning algorithms, including RFE, LASSO, RandomForest, SVM-RFE, GBDT, Bagging, XGBoost, and Boruta, were used with a machine learning model to highlight the significance of LCN2 as a key gene in sepsis-induced ARDS. Analysis of immune cell infiltration showed a positive correlation between neutrophils and LCN2. In a cell model induced by LPS, it was found that Fer-1, a ferroptosis inhibitor, was able to reverse the expression of LCN2. Knocking down LCN2 in BEAS-2B cells reversed the LPS-induced lipid peroxidation, Fe2+ levels, ACSL4, and GPX4 levels, indicating that LCN2, a FRG, plays a crucial role in mediating ferroptosis. ConclusionUpon establishing an FRG model for individuals with sepsis-induced ARDS, we determined that LCN2 could be a dependable marker for predicting survival in these patients. This finding provides a basis for more accurate ARDS diagnosis and the exploration of innovative treatment options.

Advancing wastewater treatment technologies: The role of chemical engineering simulations in environmental sustainability

Wastewater treatment stands as a critical component in mitigating environmental pollution and safeguarding public health. This review delves into the pivotal role of chemical engineering simulations in advancing wastewater treatment technologies towards enhanced environmental sustainability. The modernization of wastewater treatment processes necessitates a comprehensive understanding of the complex physical, chemical, and biological interactions involved. Chemical engineering simulations offer a powerful toolset for modeling and optimizing these processes with a focus on efficiency, effectiveness, and sustainability. Firstly, simulations enable the prediction and analysis of pollutant removal mechanisms within treatment systems. By simulating various operating conditions and configurations, engineers can optimize treatment processes to achieve higher removal efficiencies while minimizing resource consumption and waste generation. Secondly, simulations aid in the design and development of innovative treatment technologies, such as membrane filtration, advanced oxidation processes, and biological nutrient removal systems. Through computational modeling, engineers can assess the performance and feasibility of these technologies under different scenarios, facilitating informed decision-making and accelerating their implementation. Furthermore, chemical engineering simulations play a crucial role in addressing emerging challenges in wastewater treatment, including the removal of emerging contaminants such as pharmaceuticals, microplastics, and endocrine-disrupting chemicals. By simulating the behavior of these contaminants within treatment systems, engineers can devise targeted strategies for their removal, thus mitigating their adverse environmental and public health impacts. Chemical engineering simulations serve as indispensable tools for advancing wastewater treatment technologies towards greater environmental sustainability. By facilitating the optimization, design, and innovation of treatment processes, simulations contribute to the development of more efficient, cost-effective, and environmentally friendly solutions for managing wastewater and protecting our ecosystems. Embracing these simulation-driven approaches is essential for achieving the ambitious goals of sustainable development and ensuring a cleaner, healthier future for generations to come.

Abstract 5915: ADT-1004: A promising pan-RAS inhibitor for targeting KRAS mutations in pancreatic ductal adenocarcinoma

Abstract Background/Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly challenging cancer with a dismal 5-year survival rate of under 12%. More than 90% of PDAC cases involve mutations in the GTPase KRAS. Unfortunately, existing drugs targeting the RAS family, like sotorasib, exclusively address the KRAS-G12C mutation, mainly found in NSCLC. In PDAC, most patients are diagnosed at advanced stages with unresectable tumors that exhibit various genetic mutations. Approximately 70% of these cases have KRAS-G12D mutations, often co-occurring with KRAS-G12V, KRAS-G12C, and KRAS-G12R mutations. This highlights the urgent need for innovative treatments that effectively address the complex mutation landscape in PDAC and avoid resistance mechanisms associated with mutant-specific or pan-KRAS inhibitors. Methods: KPC-Luc (1 × 105) and 2838C3-Luc (1.5 × 105) PDAC cells carrying the KRAS-G12D mutation were injected into the pancreas of C57BL/6J mice. After one week, the mice were randomly divided into treatment groups (n = 7 per group) and received oral ADT-1004 at a dose of 40mg/kg body weight five times a week for four weeks. Tumor burden was assessed by bioluminescence signals using the IVIS Xenogen imaging system for patient-derived xenografts from PDAC patients with the KRAS-G12V mutation who were subcutaneously implanted in NSG mice. A week later, mice were randomized (n=7 per group) and treated orally with 40mg/kg of ADT-1004 five times a week for six weeks. Body weight and tumor size were measured twice weekly. Results: ADT-1004, a prodrug of ADT-007 that exhibits potent inhibitory effects on the proliferation of both human and murine RAS mutant PDAC cell lines with single-digit nM IC50 values, compared with µM IC50 in PDAC cells with WT RAS, was well tolerated in mice at a dose up to 175 mg/kg bid orally with sustained plasma levels of ADT-007 that exceeded IC50 values by 50-fold and even higher concentrations in pancreatic tumors. When administered orally at 40mg/kg body weight, ADT-1004 resulted in substantial growth inhibition of the KRAS-G12D and KRAS-G12V tumors, leading to profound tumor regression without any accompanying loss in body weight. ADT-1004 also displayed a significant inhibitory effect on ERK phosphorylation. Notably, this inhibition is effective regardless of the specific RAS mutational codon or isozyme, as it specifically targets activated RAS and disrupts downstream KRAS signaling pathways. Conclusion: These results highlight the promise of ADT-1004 as a potential breakthrough for treating PDAC. This novel pan-RAS inhibitor demonstrates potent inhibition of PDAC growth, irrespective of the specific KRAS mutation. Furthermore, it shows an excellent safety profile, with profound tumor regression and no impact on body weight in animal models. These findings open new possibilities for addressing the complex genetic landscape of PDAC. Citation Format: Dhana Sekhar Reddy Bandi, Purnachandra Nagaraju Ganji, Sujith Sarvesh, Yulia Maxuitenko, Jeremy B Foote, Adam B Keeton, Xi Chen, Donald Buchsbaum, Gary Piazza, Bassel El-Rayes. ADT-1004: A promising pan-RAS inhibitor for targeting KRAS mutations in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5915.

Innovative prophylactic and therapeutic approaches in liver cirrhosis.

Liver cirrhosis is the consequence of chronicisation and of the evolution of untreated liver diseases. The complexity of the disease and the complications it can cause have been and are still intensively researched, aiming to discover new therapies or improve existing ones for the effective management of liver cirrhosis. Currently, the treatment used is directed against the cause that caused the disease, if it is known; in advanced cases, liver transplantation is the only valid therapeutic option. Hepatoprotectors that are currently on the market are numerous, having as common properties the antioxidant, anti-inflammatory, stabilizing properties of the hepatocytic membrane; A few examples: the ethanolic extract of Curcuma longa, the extract from the plant called Sophora flavescens, the extract of Glycyrrhiza glabra, silymarin (extracted from Sylibum marianum), the extract of Ganoderma lucidum, etc. Liver cirrhosis is accompanied by generalized hypovitaminosis, so supplementing the diet with hydro- and liposoluble vitamins is mandatory. Protein-caloric malnutrition can be prevented by a hyperprotein diet, especially beneficial being the supplementation with branched-chain amino acids, which are also applicable in the prophylaxis and treatment of hepatic encephalopathy. Nanoparticles are a state-of-the-art therapeutic option, proving increased bioavailability, for example polydopamine nanoparticles loaded with l-arginine have been tested as therapy in liver cirrhosis. Among the innovative treatment directions in liver cirrhosis are hybrid products (e.g. hybrid polymer nanoparticles loaded with caffeic acid), cell cultures and artificial or bioartificial liver support.

An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalized Immunotherapy.

Advanced intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy characterized by limited response to standard therapeutic modalities, such as radiotherapy, chemotherapy, and targeted therapy. The prognosis for patients with advanced ICC is exceedingly bleak, with an overall survival of less than 1 year. In recent years, personalized neoantigen vaccines have emerged as a promising approach to augment the immune response against tumors. Clinical investigations are currently underway to evaluate the efficacy of neoantigen-based peptide, DNA, and dendritic cell vaccines. Herein, we present a noteworthy case of advanced ICC patients who experienced disease progression following relapse and subsequently received immunotherapy with a personalized neoantigen nanovaccine. This innovative treatment strategy involved the administration of a custom-designed neoantigen-based peptide nanovaccine tailored to the patient's specific gene mutation profile subsequent to failure of first-line therapy. The clinical efficacy and anti-tumor immune responses were evaluated using various methods, including imaging, interferon-γ ELISPOT assay, and intracellular cytokine staining. Notably, the neoantigen nanovaccine elicited a robust and specific tumor-killing effect mediated by T cells, resulting in a durable response lasting up to 25 months. These findings highlight the potential of neoantigen-based immunotherapy as a novel therapeutic avenue for the management of advanced ICC.

Neuromuscular consequences of spinal cord injury: New mechanistic insights and clinical considerations.

The spinal cord facilitates communication between the brain and the body, containing intrinsic systems that work with lower motor neurons (LMNs) to manage movement. Spinal cord injuries (SCIs) can lead to partial paralysis and dysfunctions in muscles below the injury. While traditionally this paralysis has been attributed to disruptions in the corticospinal tract, a growing body of work demonstrates LMN damage is a factor. Motor units, comprising the LMN and the muscle fibers with which they connect, are essential for voluntary movement. Our understanding of their changes post-SCI is still emerging, but the health of motor units is vital, especially when considering innovative SCI treatments like nerve transfer surgery. This review seeks to collate current literature on how SCI impact motor units and explore neuromuscular clinical implications and treatment avenues. SCI reduced motor unit number estimates, and surviving motor units had impaired signal transmission at the neuromuscular junction, force-generating capacity, and excitability, which have the potential to recover chronically, yet the underlaying mechanisms are unclear. Furthermore, electrodiagnostic evaluations can aid in assessing the health lower and upper motor neurons, identify suitable targets for nerve transfer surgeries, and detect patients with time sensitive injuries. Lastly, many electrodiagnostic abnormalities occur in both chronic and acute SCI, yet factors contributing to these abnormalities are unknown. Future studies are required to determine how motor units adapt following SCI and the clinical implications of these adaptations.

Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy.

Colorectal cancer (CRC) is the third most common cancer globally and presents a significant challenge owing to its high mortality rate and the limitations of traditional treatment options such as surgery, radiotherapy, and chemotherapy. While these treatments are foundational, they are often poorly effective owing to tumor resistance. Immunotherapy is a groundbreaking alternative that has recently emerged and offers new hope for success by exploiting the body's own immune system. This article aims to provide an extensive review of clinical trials evaluating the efficacy of various immunotherapies, including CRC vaccines, chimeric antigen receptor T-cell therapies, and immune checkpoint inhibitors. We also discuss combining CRC vaccines with monoclonal antibodies, delve into preclinical studies of novel cancer vaccines, and assess the impact of these treatment methods on patient outcomes. This review seeks to provide a deeper understanding of the current state of CRC treatment by evaluating innovative treatments and their potential to redefine the prognosis of patients with CRC.

Molecular docking, pharmacokinetic profiling and toxicity studies of 2-substituted benzimidazole derivatives against breast cancer

The most prevalent malignancy among women is breast cancer, which had almost 1.3 million new cases in 2020. It is the second most common cancer in the world, followed by lung cancer. The survival rate would be 99% if the cancerous tumour was limited to the breast. If the cancer migrated to neighbouring lymph nodes, the survival percentage would be 85% and it would drop to 27% if it spread to distant regions. In fact, the most prevalent breast cancer subtype is that caused by excessive estrogen levels. The enhancement of pertinent treatment techniques depends on the estrogen receptors (ER) in both healthy and pathological conditions. There are two primary types of ER, ERα and ERβ, which are each encoded by a different gene. ER status is the most important indicator of breast cancer prediction. To develop novel therapeutics for breast cancer, 30 newly designed benzimidazole compounds targeting the ER were docked. Among them, a compound with a glide score of −9.293 was discovered to be the leading compound. ADME investigations provided additional validation of the docking results. The pyrazole fused benzimidazole nucleus is therefore suggested as a potential pharmacophore for the development of innovative anticancer treatment for breast cancer.

The Role of Regulatory T cells (Tregs) in Tumorigenesis: A Comprehensive Literature Review

Introduction: Regulatory T cells (Tregs) are a subpopulation of CD4+ T lymphocytes that contribute to immune homeostasis by suppressing excessive immune activation. However, these immunosuppressive properties can lead to the suppression of anti-tumor immune responses. Depletion or blocking of Tregs through therapeutics has emerged as a possible method for enhancing anti-tumor immunity. However, the lack of selective targeting of Tregs in the tumor microenvironment is a significant limitation to the effectiveness of Treg therapies. Therefore, this investigation aims to review current literature on how Tregs suppress the antitumor immune response and how they can be targeted to promote anti-tumor immunity. Methods: This review examines recent literature on Tregs in the tumor microenvironment, focusing on both cell-contact dependent and independent mechanisms. Clinical trial studies were also included to assess therapeutic targeting of Tregs. The PubMed database was systematically searched for English articles from 2010 to present, supplemented by manual searches without date restrictions. Boolean expressions ensured comprehensive study retrieval. Results: The involvement of Tregs in the development of multiple cancer types is evident, and targeting these cells could potentially enhance the efficacy of antitumor immunity. In addition, we compiled a list of the novel approaches currently being used for Treg targeting in the context of cancer. Discussion: This review has identified the most promising targets for Treg-based therapies, opening avenues for accelerating the development of innovative cancer treatments. Conclusion: Our literature review offers insights into the complex interplay between the immune system and cancer. The understanding of this interaction is not just an endpoint but could potentially act as a steppingstone towards new scientific discoveries.

Engineering MnO2 Nanomulberries for Enhancing PTT/PDT Synergistic Cancer Therapy

AbstractConsidering the great catalyzation ability to degrade H2O2 into O2, MnO2 nanoparticles are utilized as nanocarriers in phototherapies for anticancer treatments to overcome the hypoxia tumor microenvironment (TME). However, the confliction of size requirement between promoting tumor delivery and cellular uptake and catalyzing H2O2 degradation limits the functions of MnO2 nanoparticles. Herein, this work presents strategy to cross‐link small‐sized MnO2 nanoparticles, during which the indocyanine green (ICG) is loaded, thus obtaining large‐sized MnO2 nanomulberries (MnINCs) for overcoming the size requirement confliction. The MnINCs present great performances in both photothermal therapy (PTT) and photodynamic therapy (PDT) effects. This work tests the therapeutic efficacy of MnINCs in various human cancer cell lines including human cervical cancer cell line (HeLa), human breast cancer cell line (MCF‐7), human hepatoma cell line (HepG‐2), human gastric carcinoma cell line (MGC803), and a Hela cell‐derived xenograft model. The satisfying growth inhibition effects are observed in all these cell lines and the tumor model. The demonstrations for using MnINCs to overcome the size requirement confliction between promoting tumor delivery and cellular uptake and catalyzing H2O2 degradation highlight the promising application potentials of the clustering strategy for developing innovative treatments in cancer therapy.

The Roots and Clinical Effects of Racial Bias in Medicine

In a growing society, healthcare has become an essential part of a country’s development, standard of living, and life expectancy. The past decade has seen unprecedented growth in both scientific and medical discoveries, leading to improved treatment plans and innovative treatments, yet there are some aspects of healthcare that remain stunted. Discrimination, particularly on the basis of race, is still prevalent and ingrained in the American healthcare system, leading to worsened patient outcomes for people of color and a discomfort with seeking medical care that disproportionately affects those in marginalized groups. This bias continues even into the education of healthcare providers, which perpetuates the cycle of prejudice in the medical field. While the intersection of racism in the medical field varies greatly and maintains its prevalence amongst different races, this dissertation focuses mainly on discrimination of Black patients in the American healthcare system. For further information on the effects of racial bias both abroad and amongst a wider variety of races, valuable resources can be found below the works cited in this review. The sources analyzed in this review are analytical and scientific, with little to no use of primary anecdotal evidence. While such an emotional topic as racism and how it affects patient care relies heavily on personal experience, these sources have confounded the feelings of many patients nationally and adapted them into a well-reviewed analysis of how those feelings reflect nationwide opinions. Furthermore, it includes historical papers detailing the foundations of the medical field and how it was developed in hand with racism. The following sections will include definitions of terminology surrounding the issue, information on the history that led to modern-day biases, the ways in which these biases are seen by patients, and how it affects their care. This will demonstrate the link between past practices and the discriminatory actions in the medical system currently. Furthermore, it will establish evidence that there are effects felt by patients of color as well as offer information on possible solutions to help better their treatment.

Editorial: Innovative treatment technologies for sustainable water and wastewater management

Editorial: Innovative treatment technologies for sustainable water and wastewater management

Innovative treatment of obstructive sleep apnoea.

Innovative treatment of obstructive sleep apnoea.